Environmentally-friendly pharmaceutical synthesis

拟议中的研究在全球制药商辉瑞公司的加拿大子公司 ** 辉瑞蒙特利尔之间建立了新的合作关系，以及麦吉尔大学的Tomislav Friscic教授的机械化学和绿色化学研究小组。辉瑞蒙特利尔公司正在积极寻求开发路线，使活性药物成分（API）的生产更简单，更环保。在这种情况下特别感兴趣的是机械化学无溶剂合成，** 应该能够在药物合成中大大 ** 减少或完全消除溶剂的使用，而溶剂是成本和环境问题的主要原因。然而，在这一点上，辉瑞蒙特利尔 ** 没有足够的化学专业知识，以继续开发无溶剂，机械化学 ** 制造，并因此正在寻求与该领域的领先专家合作。辉瑞蒙特利尔 ** 坚信，与麦吉尔大学Friscic集团的合作将使他们能够克服在开发更清洁、更安全和更高效的生产路线时遇到的障碍。

The proposed research creates a new collaborative relationship between Pfizer Montreal, a Canadian subsidiary**of the global pharmaceutical manufacturer Pfizer, Inc., and the mechanochemistry and green chemistry research**group of Prof. Tomislav Friscic at McGill University. Pfizer Montreal is actively looking to develop routes that**would make the manufacture of active pharmaceutical ingredients (APIs) simpler and more**environmentally-friendly. Of particular interest in that context is mechanochemical solvent-free synthesis that**should enable the use of solvents, which are a major reason for cost and environmental concern, to be greatly**diminished or completely eliminated from pharmaceutical synthesis. However, at this point Pfizer Montreal**does not have sufficient chemistry expertise to continue the development of solvent-free, mechanochemical**manufacturing and for that reason is looking to collaborate with a leading expert in the field. Pfizer Montreal**strongly believes that the collaboration with the Friscic group at McGill University, who are leaders in**solvent-free pharmaceutical synthesis and materials science, will enable them to overcome the hurdles**encountered in the development of cleaner, safer and more efficient manufacturing routes.